Cancer Pain vs Chronic Pain — Clinical Trial Comparison
Cancer Pain
Pain caused by tumour or cancer treatment
Chronic Non-Cancer Pain
Persistent pain lasting >3 months, unrelated to cancer
Cancer pain and chronic non-cancer pain are fundamentally different in cause, approach, and research priorities. Cancer pain is driven by tumour invasion, nerve compression, or treatment side effects, and follows the WHO analgesic ladder. Chronic non-cancer pain encompasses conditions like back pain, fibromyalgia, and neuropathic pain, where the nervous system itself is dysregulated. Their trial landscapes diverge significantly.
Key Differences at a Glance
| Feature | Cancer Pain | Chronic Non-Cancer Pain |
|---|---|---|
| Cause | Tumour invasion, nerve compression, chemotherapy-induced, radiation-induced, post-surgical | Multiple: nerve damage, central sensitisation, inflammation, musculoskeletal, psychological |
| UK prevalence | ~55–70% of advanced cancer patients; ~25–40% of early-stage | ~34% of UK adults (~22 million) experience chronic pain |
| Pain types | Nociceptive (tumour), neuropathic (nerve damage), bone pain, breakthrough pain | Nociceptive, neuropathic, nociplastic (central sensitisation), mixed |
| Treatment approach | WHO analgesic ladder: paracetamol → weak opioids → strong opioids + adjuvants | Multimodal: non-opioid medications, psychology, physiotherapy, self-management |
| Opioid use | Common and appropriate for moderate-severe cancer pain | Increasingly avoided; NICE recommends against long-term opioids |
| Prognosis | May resolve if cancer treated successfully; may progress with disease | Often long-term; management goal is function and quality of life |
Clinical Trial Availability
| Trial Aspect | Cancer Pain | Chronic Non-Cancer Pain |
|---|---|---|
| UK trials actively recruiting | 15–25 studies | 30–50 studies |
| Most common trial phase | Phase 2–3 | Phase 2–3 |
| Top interventions tested | Opioid formulations, interventional procedures (nerve blocks, ablation), cannabinoids, radiotherapy techniques | Neuromodulation, medical cannabis, digital CBT/ACT, physiotherapy, novel non-opioid analgesics |
| Interventional trials | Major category (celiac plexus block, epidural, intrathecal pumps) | Significant (spinal cord stimulation, peripheral nerve stimulation, radiofrequency ablation) |
| Psychological trials | Growing (ACT, meaning-centred therapy) | Major category (CBT, ACT, acceptance-based, mindfulness) |
| Digital health trials | Emerging (remote monitoring, telehealth) | Rapidly growing (apps, VR, wearable-guided activity) |
Exciting Emerging Treatments
Cancer Pain Trials
- Interventional neuromodulation — spinal cord stimulation and dorsal root ganglion stimulation for cancer-related neuropathic pain
- Medical cannabis and cannabinoids — THC:CBD formulations for cancer pain refractory to opioids
- Novel opioid formulations — abuse-deterrent, extended-release, and targeted delivery systems
- Bisphosphonate and denosumab optimisation — for cancer bone pain
- Interventional pain procedures — image-guided nerve blocks, neurolysis, and ablation techniques
- Virtual reality analgesia — immersive VR during painful procedures and for breakthrough pain
Chronic Pain Trials
- Spinal cord stimulation (next-gen devices) — high-frequency, burst, and closed-loop stimulation
- Medical cannabis — UK-based trials testing specific cannabinoid formulations for chronic pain
- Nerve growth factor (NGF) inhibitors — tanezumab and similar agents for osteoarthritis and chronic pain
- Digital therapeutics — app-based CBT, ACT, and pain management programmes
- Wearable-guided graded activity — technology-enabled pacing and activity management
- Transcranial magnetic stimulation (TMS) — non-invasive brain stimulation for chronic pain modulation
💡 Breakthrough cancer pain is a specific trial category
Breakthrough pain — sudden, severe pain flares despite stable background pain medication — affects 50–80% of cancer pain patients. Several UK trials specifically target breakthrough pain with rapid-onset fentanyl formulations, intranasal analgesics, and patient-controlled devices. If you experience breakthrough pain, this is a distinct trial eligibility pathway.
Eligibility Differences
Cancer Pain Trial Criteria
- Confirmed cancer diagnosis with pain attributed to cancer or its treatment
- Pain severity scoring (NRS/VAS ≥ 4 for most trials)
- Cancer stage and treatment status specified (some trials require active treatment, others palliative)
- Current analgesic regimen documented — some trials require stable opioid doses
- Life expectancy considerations — some trials have minimum life expectancy requirements
Chronic Pain Trial Criteria
- Chronic pain duration ≥ 3–6 months, non-cancer origin
- Pain mechanism categorised (nociceptive, neuropathic, nociplastic, mixed)
- Severity thresholds (typically NRS ≥ 4 or Brief Pain Inventory scores)
- Failed standard treatments documented for interventional trials
- Psychological screening — some trials assess for depression/anxiety that may confound outcomes
🎗️ Cancer Pain Trials
Find actively recruiting cancer pain clinical trials across the UK
View Cancer Pain Trials⚡ Chronic Pain Trials
Find actively recruiting chronic pain clinical trials across the UK
View Chronic Pain Trials